April 03, 2025
ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.
April 03, 2025
ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly.
April 02, 2025
A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.
April 01, 2025
Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.
April 01, 2025
In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.
March 31, 2025
ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.
March 31, 2025
Lepodisiran at 400 mg maintained reductions of Lp(a), an inherited risk factor for cardiovascular disease, at ~90% at 1 year and ~75% at 1.5 years, Eli Lilly reported.
March 31, 2025
Dupilumab significantly improved measures of severe AD, including EASI and IGA, as well as pruritis in pediatric populations aged 6 months to 18 years vs placebo.
March 28, 2025
In the pediatric population aged 0 to 19 years, exposure to fentanyl was through intentional use by two-thirds, investigators found.
March 28, 2025
The 2025 measles outbreak is predominantly affecting children, but measles is highly contagious and adults remain at risk, especially if they have not received the MMR vaccination.